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doi:10.1016/j.kjms.2011.11.008Abstract A 44-year-old man had a brain tumor secondary to lung adenocarcinoma and under-
went craniectomy to remove the brain tumor. After postoperative whole-brain radiation
therapy, he underwent pneumonectomy followed by chemotherapy, mediastinal radiotherapy,
and target therapy for lung cancer. Thirty-six months after the initial brain surgery, he suffered
from neck pain and right upper limb numbness that rapidly progressed to upper extremity
weakness and paralysis in 2 months. Magnetic resonance imaging demonstrated an intramedul-
lary spinal cord lesion at the C4 level. Laminectomy and gross intramedullary tumor removal
were performed. The patient’s neurological function improved after the operation. Neverthe-
less, 4 months after the intramedullary tumor removal, he began to show multiple metastases.
Unfortunately, the patient died from respiratory failure 8 months after diagnosis with intrame-
dullary spinal cord metastasis. In this case, early diagnosis and aggressive surgical treatment
combined with postoperative radiotherapy and chemotherapy might have provided this patient
with a prolonged survival and better quality of life.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.of Neurosurgery, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung 807, Taiwan.
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diagnostic anomaly (Fig. 1A). Brain magnetic resonanceLung cancer is a common and fatal malignancy [1]. Metas-
tases to the central nervous system such as the brain and
meninges are often seen in patients with primary lung
cancer [2]. However, intramedullary spinal cord metastasis
(ISCM) from lung cancer is relatively rare compared with
other system malignancies. Among cases of metastasis to
the central nervous system (CNS), the frequency of ISCM is
4.2e8.5% in published autopsy reports [3e5].
The clinical features of ISCM have been described as
a rapidly progressive neurological deficit [6]. Therefore,
prognosis of ISCM is poor [7]. In a cohort study, individuals
with brain metastases show a median survival time of 2.7
months after first admission with brain metastases. For lung
cancer patients with brain metastasis, the survival time is
even shorter. On average, these patients survive 2.5 months
after their first admission with brain metastases [8].
Involvement of other sites within the CNS has been
shown to be common in patients with ISCM. In Schiff and
O’Neill’s report, 32.5% of patients with ISCM had a history
of brain metastasis preceding the diagnosis of ISCM [9].
The published medical literature rarely shows a good
long-term survival in patients with primary lung cancer and
brain metastasis. Moreover, the prognosis of patients with
primary lung cancer and brain metastasis deteriorating to
ISCM is worse.
In this report, we present a patient with metachronous
brain and ISCM from lung cancer.
Case report
A 44-year-old man was transferred to the neurosurgery
department due to a 2-week history of headache, dizziness,
and left leg numbness. He had a one-pack-a-day history of
smoking lasting more than 20 years. His Karnofsky Perfor-
mance Status (KPS) was 90%, without any adverse prognostic
factors such as weight loss or laboratory abnormalities.Figure 1. (A) Chest plain film showing no definite diagnostic ano
disease in the middle mediastinum (white arrow) with partial atelHis preoperative chest X-ray film showed no definite
imaging (MRI) found a heterogeneous nodule in the right
postcentral gyrus (Fig. 2A). The cerebral lesion was
completely surgically removed (Fig. 2B). Pathology
revealed a metastatic adenocarcinoma, and immunohisto-
chemical studies showed positivity for both TTF-1 and CK 7
(Fig. 3AeC), suggesting a pulmonary origin. Whole-brain
radiation therapy (WBRT), consisting of a total dose of
3400 cGy in 200-cGy daily fractions, was administered
postoperatively.
Chest computed tomography (CT) was performed and
revealed metastatic disease in the middle mediastinum (see
Fig. 1B). An endobronchial lesion was found on bronchos-
copy, and the biopsy demonstrated bronchogenic adeno-
carcinoma. Left pneumonectomy was performed after
WBRT. Pathology revealed a moderately differentiated, lung
adenocarcinoma (pT2N1M1) (Fig. 3D).
After lung surgery, the patient’s KPS remained at 90%.
He underwent five courses of chemotherapy with paclitaxel
and cisplatin. Subsequently, positron emission tomography
found multiple intense foci of fludeoxyglucose-avid lesions
in the mediastinal lymph nodes and left posterior cervical
lymph nodes. As a metastatic lesion was highly suspected,
radiotherapy with a total dose of 5220 cGy for a medias-
tinal metastasis was performed. In addition, the patient
continued chemotherapy with two courses of paclitaxel
alone, one course of intravenous vinorelbine, and six
courses of pemetrexed. In addition, he had target therapy
with gefitnib for 2 months.
Three years after the initial brain surgery, the patient
began to suffer from neck soreness followed by right upper
limb numbness. Two months later, these neurological
symptoms rapidly progressed to upper extremity weakness
and paralysis. At that time, his KPS was 60%. The cervical
spine MRI showed an intramedullary tumor at C4 level
(Fig. 4A). Therefore, he underwent C3eC5 laminectomy
with gross removal of the C4 intramedullary tumor. The
surgical pathology revealed a metastatic adenocarcinomamaly. (B) A chest computed tomography scan shows metastatic
ectasis of the left lingular lobe (black arrows).
Figure 2. (A) Contrast-enhanced T1-weighted imaging shows a heterogeneous nodule with mild gadolinium enhancement in the
right postcentral gyrus (arrow). Perinodular hyperintensity can be noted. (B) Two years after brain surgery, contrast-enhanced fast
fluid-attenuated inversion-recovery (FLAIR) imaging shows that the tumor has been completely removed without recurrence.
Figure 3. (A) The brain shows metastatic adenocarcinoma composed of hyperchromatic nuclei and pleomorphic tumor cells
arranged in a papillary glandular or cribriform pattern. H&E, 200. (B) The tumor cells of the metastatic lesion (brain) are
immunopositive for TTF-1. TTF-1 immunohistochemical stain, 200. (C) The tumor cells of the metastatic lesion (brain) are
immunopositive for CK7. CK-7 immunohistochemical stain, 200. (D) Histologically, the left lung shows features of adenocarci-
noma. H&E, 200. (E) The cervical cord shows metastatic adenocarcinoma composed of cancerous cells with moderate pleo-
morphism arranged in a glandular or villoglandular pattern. H&E, 200.
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Figure 4. (A) Contrast-enhanced T1-weighted imaging showing an intramedullary tumor with marked ring enhancement (arrow).
(B) Four months after cervical spine surgery, a -enhanced T1-weighted image shows a small part of the residual intramedullary
tumor at the level of the C4 spinal cord and edema. A metastatic brain tumor is in the cerebellum (circle).
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department. His neurological symptoms and signs subsided,
and his KPS returned to 80%.
Four months later, the patient’s follow-up chest CT
found several osteoblastic metastatic lesions in the spine
and ribs bilaterally. A bone scan revealed multiple bone
metastases from lung cancer. Brain MRI revealed multiple
metastatic brain tumors in the cerebrum, cerebellum, and
subependymal area. Hence, chemotherapy with two cour-
ses of gemcitabine was given concurrently with radio-
therapy consisting of a total dose of 3000 cGy in 300-cGy
daily fractions, for lumbar spine and sacroiliac joint
metastases. In addition, he underwent radiotherapy, con-
sisting of a total dose of 3060 cGy in 340-cGy daily fractions,
for brain metastases.
The patient became weaker and developed shortness of
breath. He was admitted to the hospice ward for palliative
treatment and unfortunately died from respiratory failure 8
months after the diagnosis of ISCM.Discussion
Patients with lung cancer and brain metastasis have a poor
prognosis. Surgery plus postoperative WBRT provides
a favorable prognosis for patient with a single metastatic
brain tumor [10,11]. Many studies have recommended
surgery for the primary lung tumor, suggesting a longer
functional survival than without surgical intervention
[12,13]. Nevertheless, Billing et al. [14] suggested that
surgical resection provides benefit only in patients without
lymph nodes metastases. They reported that no patient
with mediastinal lymph node involvement survived longer
than 3 years. In our report, this 4-year survivor underwent
dual resection of both the lung primary and brainmetastases followed by radiotherapy, chemotherapy, and
target therapy. We deem that aggressive treatment for lung
cancer with brain metastasis is an optimal approach that
would lead to a favorable prognosis.
ISCM represents a rare evolution of cancer from systemic
cancer, and it is a challenge in terms of diagnosis and
treatment. Prior to the advent of MRI, many diagnoses were
established post mortem [3e5]. Gadolinium-enhanced MRI
shows a high sensitivity and has become the gold standard
in diagnosis of this disease [9,15,16]. Nowadays, other
diagnostic tests, such as plain radiographs of spine and
cerebrospinal fluid analysis, have comparatively less value
in the diagnosis of ISCM [9].
Lung cancer and breast cancer represent the most
common primary sources of extra-CNS ISCM, with lung
cancer accounting for almost half of the cases [7,9,17].
ISCM may occur at any level of the spinal cord. In a review
article [7], 147 patients with ISCM were analyzed. Metas-
tasis to the cervical cord was most common (42%), which
might relate to the greater bulk and richer vascular supply
in the cervical cord [18].
Previous studies illustrated three pathways of ISCM,
including hematogenous spread [7,19], direct intra-
medullary invasion by meningeal carcinomatosis [20], and
direct invasion from a contiguous structure [3,20]. With the
evidence of multiple CNS metastases from lung cancer, we
postulate that the most likely pathway is via the arterial
route, as well as direct extension via cerebrospinal fluid
distribution from the central canal into the intramedullary
space.
From a treatment perspective, we consider surgical
resection to be the optimal treatment for patient with
ISCM. In the medical literature [16,20], radiotherapy is
often indicated for patients with ISCM; even so, surgical
resection for intramedullary spinal cord tumor can also be
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a favorable prognosis [21e24]. In the present case, the
patient’s neurological function improved after surgery. We
believe that surgery would provide a favorable internal
decompression, which is helpful to relieve the rapid
neurological deterioration.
The duration between a patient’s initially diagnosed
tumor and ISCM has been shown to be 25 months on
average, the mean period between the occurrence of the
patient’s symptom and the diagnosis with ISCM being 52
days [7]. In our case, this patient was diagnosed with ISCM
38 months after the diagnosis of his primary lung cancer.
We believe that the prolonged survival of this patient is
the result of increased awareness of the condition and
an improvement in investigative techniques, as well as
aggressive surgical treatment with postoperative adjuvant
chemotherapy and radiotherapy.References
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